文献速递免疫规划传染病防控与疫情报告

基于人群登记数据评估台湾地区2023-2024流感季老年人流感疫苗有效性

Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season.
PubMed 文献 · Vaccine · 2025-09-05

本研究利用台湾地区国家数据库开展回顾性队列研究,评估2023-2024流感季≥65岁成年人流感疫苗有效性。在4,174,655名个体中,1,833,476人(44%)接种疫苗;调整后疫苗有效性从门诊就诊的29.6%至重症的75.2%不等,对流感样疾病门诊就诊为21.2%,对住院就诊为37.8%,对30天内全因死亡为48.2%。结论认为流感疫苗接种对实验室确诊流感和流感样疾病具有中至高度有效性。

要点

  • 在≥65岁老年人中,流感疫苗接种对实验室确诊流感结局的调整后疫苗有效性为29.6%(门诊就诊)至75.2%(重症)。
  • 对流感样疾病门诊就诊的疫苗有效性为21.2%,对住院就诊为37.8%,对30天内全因死亡为48.2%。
  • 协变量调整后疫苗有效性估计值升高,尤其对重症结局;倾向性评分匹配分析结果一致。

核心结论

  • 流感疫苗接种对老年人实验室确诊流感和流感样疾病具有中至高度有效性,保护作用见于门诊就诊、住院和死亡结局。

研究设计与样本

  • 回顾性队列研究,纳入≥65岁成年人,评估2023-2024流感季疫苗有效性。
  • 疫苗接种组为2023年10月2日至11月15日期间接种者,无该期间接种记录者为未接种组。
  • 观察期从接种后14天(索引日期)开始至2024年2月15日;未接种者索引日期为2023年10月2日。
  • 结局和协变量数据来自链接的国家数据库,疫苗有效性采用调整逻辑回归模型估计,并用倾向性评分匹配进行敏感性分析。
  • 共纳入4,174,655名个体,其中1,833,476人(44%)接种疫苗。

主要发现

  • 流感疫苗接种对实验室确诊流感结局的调整后疫苗有效性范围为29.6%(门诊就诊)至75.2%(重症)。
  • 对流感样疾病门诊就诊的疫苗有效性为21.2%,对住院就诊为37.8%,对30天内全因死亡为48.2%。
  • 协变量调整后疫苗有效性估计值升高,尤其对重症结局。
  • 倾向性评分匹配分析结果与主要分析一致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Influenza infection can cause serious complications in the elderly, including hospitalizations and death. In Taiwan, government-funded influenza vaccination is offered to the elderly ≥65 years old. We aim to evaluate vaccine effectiveness (VE) among this group during 2023-2024 influenza season using national databases. METHODS: A retrospective cohort study was conducted to evaluate VE among adults aged ≥65 years. Individuals were grouped by vaccination status: those vaccinated between October 2 and November 15, 2023 comprised the vaccinated group, while those without vaccination records during this period formed the unvaccinated group. The observation period began 14 days after vaccination (index date) and continued through February 15, 2024; for unvaccinated individuals, the index date was October 2, 2023. Outcome and covariate data were obtained from linked national databases. VE was estimated using adjusted logistic regression models, with sensitivity analyses using propensity score matching. RESULTS: Among 4,174,655 individuals, 1,833,476 (44 %) were vaccinated. Influenza vaccination showed moderate to high effectiveness against laboratory-confirmed influenza outcomes, with adjusted VE ranging from 29.6 % (outpatient visits) to 75.2 % (severe disease). Moderate effectiveness was observed against influenza-like illness outpatient visits (VE: 21.2 %), inpatient visits (37.8 %) and all-cause mortality within 30 days (48.2 %). VE estimates increased after covariate adjustment, especially for severe outcomes. Findings were consistent in analyses using propensity score matching. CONCLUSIONS: Influenza vaccination was moderately to highly effective against both laboratory-confirmed influenza and influenza-like illness in elderly adults. Protection was observed across outpatient visits, hospitalizations, and mortality.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang YT, Tsou TP, Kuo SH, et al. Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season. Vaccine. 2025. PMID: 40913816. doi:10.1016/j.vaccine.2025.127690

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。